Virtu Financial LLC Invests $1.59 Million in BioNTech SE (NASDAQ:BNTX)

Virtu Financial LLC bought a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 19,742 shares of the company’s stock, valued at approximately $1,586,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. GAMMA Investing LLC boosted its stake in shares of BioNTech by 121.0% during the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock worth $25,000 after acquiring an additional 150 shares during the last quarter. Frazier Financial Advisors LLC purchased a new position in BioNTech during the fourth quarter valued at $30,000. Covestor Ltd lifted its position in BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% during the first quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the period. Finally, Crewe Advisors LLC purchased a new stake in BioNTech in the first quarter worth about $75,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

BioNTech Price Performance

NASDAQ:BNTX opened at $124.71 on Wednesday. The company has a market capitalization of $29.65 billion, a P/E ratio of 249.42 and a beta of 0.23. The business’s 50-day moving average is $88.13 and its 200 day moving average is $89.90. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01. BioNTech SE has a 12 month low of $76.53 and a 12 month high of $131.49.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same period in the previous year, the company earned ($0.86) EPS. BioNTech’s revenue for the quarter was down 23.3% compared to the same quarter last year. On average, equities research analysts forecast that BioNTech SE will post -2.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on BNTX. HC Wainwright reaffirmed a “buy” rating and set a $113.00 price objective on shares of BioNTech in a research report on Monday. Hsbc Global Res raised shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. HSBC upgraded shares of BioNTech from a “hold” rating to a “buy” rating in a research report on Friday, August 2nd. TD Cowen decreased their price objective on shares of BioNTech from $98.00 to $85.00 and set a “hold” rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. upgraded shares of BioNTech from an “underweight” rating to a “neutral” rating and lifted their target price for the company from $91.00 to $125.00 in a research note on Monday. Six analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, BioNTech has an average rating of “Moderate Buy” and an average target price of $118.00.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.